Comparative safety of tetracycline, minocycline, and doxycycline

L. E. Shapiro, S. R. Knowles and N. H. Shear
Department of Medicine, Sunnybrook Hospital, University of Toronto Medical School, Ontario, Canada.

BACKGROUND: Because minocycline can cause serious adverse events including hypersensitivity syndrome reaction (HSR), serum sicknesslike reaction (SSLR), and drug-induced lupus, a follow-up study based on a retrospective review of our Drug Safety Clinic and the Health Protection Branch databases and a literature review was conducted to determine if similar rare events are associated with tetracycline and doxycycline. Cases of isolated single organ dysfunction (SOD) attributable to the use of these antibiotics also were identified. OBSERVATIONS: Nineteen cases of HSR due to minocycline, 2 due to tetracycline, and 1 due to doxycycline were identified. Eleven cases of SSLR due to minocycline, 3 due to tetracycline, and 2 due to doxycycline were identified. All 33 cases of drug-induced lupus were attributable to minocycline. Forty cases of SOD from minocycline, 37 cases from tetracycline, and 6 from doxycycline were detected. Hypersensitivity syndrome reaction, SSLR, and SOD occur on average within 4 weeks of therapy, whereas minocycline-induced lupus occurs on average 2 years after the initiation of therapy. CONCLUSIONS: Early serious events occurring during the course of tetracycline antibiotic treatment include HSR, SSLR, and SOD. Drug-induced lupus, which occurs late in the course of therapy, is reported only with minocycline. We theorize that minocycline metabolism may account for the increased frequency of serious adverse events with this drug.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cutaneous Reactions to Drugs in Children
Segal et al.
Pediatrics 2007;120:e1082-e1096.
ABSTRACT | FULL TEXT  

Inhibition of Mammalian mitochondrial protein synthesis by oxazolidinones.
McKee et al.
Antimicrob. Agents Chemother. 2006;50:2042-2049.
ABSTRACT | FULL TEXT  

The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.
Braithwaite et al.
Med Decis Making 2006;26:182-193.
ABSTRACT  

Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
Wells et al.
Brain 2003;126:1628-1637.
ABSTRACT | FULL TEXT  

Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis
Brundula et al.
Brain 2002;125:1297-1308.
ABSTRACT | FULL TEXT  

Tetracyclines in Pediatrics Revisited
Shetty
CLIN PEDIATR 2002;41:203-209.
 

Drug-Induced Hypersensitivity Syndrome in Pediatric Patients
Carroll et al.
Pediatrics 2001;108:485-492.
ABSTRACT | FULL TEXT  

Drug-Induced Lupus Associated With COL-3: Report of 3 Cases
Ghate et al.
Arch Dermatol 2001;137:471-474.
ABSTRACT | FULL TEXT  

Minocycline-induced lupus: clinical features and response to rechallenge
Lawson et al.
Rheumatology (Oxford) 2001;40:329-335.
ABSTRACT | FULL TEXT  

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
Rudek et al.
JCO 2001;19:584-592.
ABSTRACT | FULL TEXT  

The Use of Tetracyclines for the Treatment of Sarcoidosis
Bachelez et al.
Arch Dermatol 2001;137:69-73.
ABSTRACT | FULL TEXT  

Is Serum Sickness an Uncommon Adverse Effect of Minocycline Treatment?
Malakar et al.
Arch Dermatol 2001;137:100-101.
FULL TEXT  

Minocycline in Acne Is Still an Issue
Corona
Arch Dermatol 2000;136:1143-1145.
FULL TEXT  

Minocycline-induced clinical and biological lupus-like disease
Tournigand et al.
Lupus 1999;8:773-774.
ABSTRACT  

Minocycline-induced lupus and autoimmune phenomena
McHugh
Lupus 1999;8:417-418.
 

Antimicrobial Photosensitive Reactions
Vassileva et al.
Arch Intern Med 1998;158:1993-2000.
ABSTRACT | FULL TEXT  

Human Herpesviruses 6 and 7: New Roles Yet to Be Discovered?
Le Cleach et al.
Arch Dermatol 1998;134:1155-1157.
FULL TEXT